Open AccessNemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study
Author(s) -
William A Fahy,
Farshid Homayoun-Valiani,
Anthony Cahn,
Jonathan Robertson,
A.G.B. Templeton,
Wilhelmine Meeraus,
Robert Wilson,
M. Lowings,
Miriam Marotti,
Sarah West,
Maggie Tabberer,
Edith M. Hessel
Publication year - 2021
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s309320
Subject(s) - medicine , exacerbation , copd , placebo , tolerability , clinical endpoint , adverse effect , bronchodilator , placebo controlled study , rate ratio , randomized controlled trial , anesthesia , confidence interval , asthma , double blind , alternative medicine , pathology
Management of acute exacerbations of chronic obstructive pulmonary disease (COPD) is sometimes inadequate leading to either prolonged duration and/or an increased risk of recurrent exacerbations in the period following the initial event.